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Objective: To assess the efficacy and safety of meropenem, administered on a compassionate basis to 62 cystic fibrosis 
(CF) patients (age: 24?6 years) with hypersensitivity reactions to p-lactam antibiotics and/or infection by bacteria 
resistant to other antibiotics. 
Methods: Fifty-seven patients were chronically infected with fseudomonas aeruginosa and 5 with Burkholderia cepacia. 
In total, 124 courses (1 to  6/patient) of meropenem, 2 g three times a day by intravenous infusion (10 to 15 min) for 14 
days, were administered. 
Results: During treatment for F1 aeruginosa the mean increase in pulmonary function (as a percentage of the predictive 
values) was 5.6% for FEVI (forced expiratory volume in the first second) and 8.6% for FVC (forced vital capacity). C- 
reactive protein and erythrocyte sedimentation rate (ESR) and leukocyte count decreased significantly. In courses 
administered for chronic infection with 5. cepacia the post treatment FEVl and FVC values were higher than the pre- 
treatment values, and all the inflammatory parameters decreased. 
The geometric means of minimal inhibitory concentration (MICs) (pg/mL) for F! aeruginosa (5. cepacia) were: 
tobramycin 6 (59), ciprofloxacin 1.2 (9.7), piperacillin 49 (16.31, ceftazidime 26 (231, aztreonam 26 (35), imipenem 6.4 (not 
determined) and meropenem 5.1 (4.8). No statistically significant increase in the MlCs of meropenem for either pathogen 
occurred during therapy. Of the 124 courses, 115 were tolerated without any clinical complaint. The following side effects 
were observed: nausea (0.8%), itching (4%), rash (3.2%), drug fever (1.6%). 
Conclusions: Meropenem proved to  be a valuable drug in  the treatment of CF patients with chronic pulmonary infection 
with multiresistant F! aeruginosa and 5. cepacia and with hypersensitivity reactions to  other p-lactam drugs. 
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INTRODUCTION 
The principal cause of morbidity and mortality in cystic 
fibrosis (CF) is chronic respiratory tract infection, in 
particular infection caused by Pseudomonas aeruginosa 
and Burkholderia cepacia. Although I? aevuginosa and B. 
cepacia are rai-ely eradicated in these patients, intensive 
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antibiotic treatment of I? aeruginosa lung infection is 
associated with considerable improvement of prognosis 
[l]. The treatment of I? aeruginosa lung infection at the 
Danish CF Centre consists of the combination of a p- 
lactam antibiotic with an aminoglycoside administered 
intravenously for a period of 14 days, every third 
month. In most cases, treatment is supplemented with 
inhaled colistin methanesulfonate and oral fluoro- 
quinolones. The repeated use of p-lactam antibiotics 
may be restricted, however, by the emergence of 
resistant strains of I? aevuginora [2] and by development 
of hypersensitivity [3-51. Treatment of these patients is 
then limited to monotherapy with aminoglycosides, 
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which is considered less effective [6]. Furthermore, the 
sensitivity of l? aeruginosa to tobramycin has also 
diminished (Ciofu, unpublished results). Treatment of 
chronic B. cepacia infection is often a problem, as this 
organism is resistant to aminoglycosides and usually also 
to all the currently available p-lactam antibiotics. 
Treatment options are generally limited to ceftazidime, 
tetracycline or sulfamethoxazole with trimethoprim, 
if the infective strain is sensitive to these drugs. 
Unfortunately, development of resistance is very 
common and B. cepacia lung infection is associated with 
a poor long-term prognosis in patients experiencing 
pulmonary exacerbation [7] .  
Meropenem is a new carbapenem drug with good 
activity in vitro against l? aeruginosa and B. cepacia [8,9]. 
An initial trial of meropenem in patients with CF and 
chronic lung infection with l? aeruginosa has shown that 
it is a promising new drug, as treatment seems safe and 
effective with only slight increase in transaminases [lo]. 
This paper describes the use of meropenem on a 
compassionate use basis in CF patients who could not 
receive p-lactam antibiotics either because of severe 
hypersensitivity reactions or because of infection with 
resistant strains. In such patients comparative trials 
cannot be carried out due to the lack of other efficient 
antibiotics. 
PATIENTS AND METHODS 
Patients 
Sixty-two CF patients with chronic broncho- 
pulmonary infection, who had been treated on a 
compassionate basis with meropenein either alone or in 
combination with tobramycin and/or ciprofloxacin, 
were included in this retrospective analysis. They 
comprised 57 patients infected with l? aeruginosa, 33 
males (aged 10 to 36 years, mean 25) and 24 females 
(aged 18 to 28 years, mean 23), and five infected with 
B. cepacia, three males (aged 14, 18 and 31 years) and 
two females (aged 15 and 21 years). 
Patients admitted for treatment for I? aeruginosa or 
B. cepacia lung infection were considered for mero- 
penem treatment whenever treatment with piperacillin, 
cefsulodin, ceftazidime, aztreonam or imipenem was 
impossible because of bacterial resistance or previous 
hypersensitivity reactions. The dose of meropenem was 
120 mg/kg body weight per day up to a maximum of 
6 g/day, divided into three doses and administered by 
slow intravenous infusion (1 5 min) . The kidney function 
of the patients was assessed by Cr-EDTA clearance 
done once a year, and in patients with reduced clearance 
a reduced dose of meropenem was given. Treatment 
was provided free of charge by Zeneca Pharma- 
ceuticals, UK, on a strict named patient basis. 
Patients with previous severe type 1 hyper- 
sensitivity reactions to other p-lactams were tested with 
an epicutaneous test with meropenem diluted in 
isotonic saline (final concentration 100 mg/mL) with 
ensuing intravenous administration of increasing test 
doses as previously described [l l] .  
Depending on the clinical condition of the 
patients, the meropenem treatment might be supple- 
mented with intravenous tobramycin (dose I0  mg/kg 
body weight, or lower to keep trough values below 
1 pg/mL), oral ciprofloxacin (dose 20 to 40 mg/kg 
body weight) or a combination of the two drugs. Main- 
tenance therapy with inhaled colistin methanesulfonate 
(2 million units twice a day) for Z? aeruginosa and inhaled 
ceftazidime (2 g twice a day) for B. cepacia was con- 
tinued in all patients during the treatment period. 
Bacteriology 
The minimal inhibitory concentrations (MICs) and 
ICsos (see below) of piperacillin, ceftazidime, cipro- 
floxacin, tobramycin, aztreonam, imipenem and mero- 
penem against 90 Z? aeruginosa strains isolated in 1994 
from 90 CF patients and five B. cepacia strains isolated 
in the same year from five CF patients were measured 
by agar dilution, with an inoculum of lo3 CFU/spot. 
The MIC (MIC=ICloo) was considered the lowest 
antibiotic concentration at which no growth was 
visible. The ICso was defined as the antibiotic concen- 
tration at which 50% of the inoculum was inhibited as 
assessed by the Karber method 1121. The following 
breakpoints were used for classification of the isolates 
as resistant: piperacillin, MIC 2128 pg/mL; cefta- 
zidime and aztreonam, MIC 232 pg/mL; tobramycin, 
MIC 2 16 pg/mL; ciprofloxacin MIC 2 4 pg/mL; imi- 
penem, meropenem MIC 2 16 pg/mL [13]. In the 
event of growth of a mixed population, the most 
resistant strain was used in the evaluation. Meropenem 
MIC values before and after treatment were followed 
in 10 patients. 
Clinical efficacy and safety parameters 
Clinical efficacy was evaluated by changes in pulmon- 
ary function, changes in the hematologic inflammatory 
parameters and changes in clinical condition. Pulmon- 
ary function was tested with an electronic spirometer 
(SpirotronB, Drager, Herlev, Denmark). The forced 
vital capacity (FVC) and forced expiratory volume in 
the first second (FEVI) were recorded. Values were 
expressed as percentages ofprehctive value for same sex 
and height. Hematologic inflammatory parameters 
included C-reactive protein, erythrocyte sedimentation 
rate (ESR), and blood leukocyte count. Other 
laboratory tests included hemoglobin, Coombs test, 
thrombocyte counts, alanine aminotransferase, alkaline 
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phosphatase, bilirubin, blood urea nitrogen, p -  
creatinine, sodium and potassium. Pulmonary and 
laboratory evaluations were performed prior to the 
treatment, after 3 week and then at the end of the 
2 weeks of ineropenem treatment. AU parameters 
were routine parameters for CF patients receiving 
intravenous antipseudomonal treatment, except the 
Coonibs test, which was done at the suggestion of the 
pharmaceutical company. 
Statistical methods 
For statistical analysis the pre- and post-treatment 
values of the first administration of meropenem were 
conipared. These treatments included both mero- 
penein monotherapy and meropenem in conibination 
with tobrainycin and/or ciprofloxacin. 
The level of statistical significance used was 5% 
(two-tailed test) for all comparisons and the statistical 
analysis was conducted using the ‘StatViewTM 512+’ 
program (01986 Abacus Concepts, Inc.). 
FEV, and FVC values pre- and post-treatment 
were compared using ANOVA for repeated measures. 
Results are presented as means and standard deviations. 
Pre- and post-treatment values of the leukocyte count, 
ESR and C-reactive protein were compared using the 
Wilcoxon sign rank test for non-parametric paired data, 
because the distribution of the data was not normal. 
Kesults are presented as medians and ranges. 
RESULTS 
Sixty-two CF patients with chronic bronchopulmonary 
infection (57 with P aeruxinosa and five with B. cepacia) 
were included in this retrospective analysis. A total 
of 1 14 courses of meropenem were administered to the 
I? nevu~~inosa-iiifected patients (range 1 to 6 courses/ 
patient) and a total of 10 courses to the B. cepacia 
infected patients (range 1 to 3 courses/patient). Fifty- 
one of the 124 courses were monotherapy with 
nieropenem, 3 1 were in combination with tobrarnycin, 
11 in combination with ciprofloxacin and 21 in 
combination with both tobraniycin and ciprofloxacin . 
Three courses administered for I! aevugirzosa (all of them 
monotherapy with meropenem) were stopped after a 
few days because of adverse reactions (see below). One 
hundred and eleven completed courses could be 
evaluated. One of the 10 courses administered for the 
B. cepacia infection had been interrupted because of 
drug fever. 
Chronic I? aeruginosa infection 
The clinical condition, evaluated by examination, was 
improved in 79 and remained unchanged in 32 of the 
1 I1  courses. 
Pulmonary function 
Data on the pulmonary function before and after 
J M O S ~ ,  are treatment in patients infected with I? arruk’ 
given in Table 1.  The mean change in FEVl during the 
first course was 5.6%. This was statistically significant 
using the F-test (Fz32.397, p=0.0001). This was also 
reflected in the FVC values. The mean change was 
8.594, with F=32.955 and p=0.0001. It can be seen 
that the post-treatment mean values are higher than the 
pretreatment mean values irrespective of the combina- 
tion of antibiotics received. Eighteen of 57 CF patients 
with chronic I? aeruginosa infection received a t  least 
three nieropenern courses. The results of the first three 
courses are given in Table 2. It can be seen that the 
efficacy of the treatment appeared to be maintained 
after repeated courses. 
Table 1 Pulmonv function parameters before and after treatment with meropenem 
_ _ _ _ _ _ _ _ _ _ ~  ~ ~ 
FEVi FVC 
Treatment, 
no course? Before After Before After 
~~~~~~ ~ ~ 
First course, 
54 Mean 46.8 52.4 71.2 79.0 
SD 24.8 25.5 28.8 26.8 
M, 48 Mean 47.4 54.3 74.9 x7.7 
SD 20.4 21 23 21.1 
MT, 31 Mean 38.1 41 .V 63.2 67.9 
SD 20.7 21.1 26.9 23.5 
MC, 11 Mean 54.6 60.1 76.7 88.3 
SD 31.4 35.1 35.6 38.7 
MTC, 21 Mean 31.2 35.7 56 62.8 
SD 19.7 22.6 22.8 24 
First course in each patient, as monotherapy (M) or in association with tobramycin (MT) and/or clprofloxacin (MTC)/(MC) for 
P uerugirrosu infection. FEVl and FVC are expressed as percentage of the predzctive values for sex and height. 
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Table 2 Pulmonary function parameters before and after treatment with nieropenem after the first three courses 
administered for I? aeruginosa infection in 18 patients 
FEVi FVC 
Before After Before After 
1st course Mean 36.9 41.2 60.9 71.8 
SD 22.5 22.4 27.6 25.6 
2nd course Mean 36.4 42.2 61.7 73.3 
SD 19 22.9 25.6 30 
3rd course Mean 34.9 38.4 60.7 68.1 
SD 17.2 17 31.2 28.5 
FEVl and FVC are expressed as percentages of the predictive values for sex and height. 
Inflammatory parameters 
The leukocyte count, ESR and C-reactive protein 
values after treatment were significantly lower than the 
values before treatment (p=0.02 for leukocyte count 
and p=O.OOOl for ESR and C-reactive protein) (Table 
3). The values before and after treatment for the 
different combination therapies are given in Table 4. It 
can be seen that the post-treatment values are lower 
than those before treatment, with monotherapy and 
with any antibiotic combination. 
Chronic B. cepacia infection 
The results of the meropenem treatment (nine courses) 
in five patients with B. cepacia infection are shown in 
Tables 5 and 6. The mean values of FEVl and FVC after 
the treatment were higher than the pretreatment values. 
The medians for leukocyte count, C-reactive protein 
and the ESR had decreased after treatment. Due to the 
small number of patients, no statistical significance was 
calculated. The clinical condition improved in six of 
the courses and it remained unchanged in three of the 
courses. None of the patients deteriorated during the 
treatment courses. 
Table 3 Inflammatory parameters before and after treatment with meropenem for P aerqinora infection 
Leukocyte count ESR C-reactive protein 
(1091~) (mm/h) (mg/Y 
Before After Before After Before After 
Meman 8.3 7.3 20 18 98 48 
Range 5-27 4-13 2-98 3-84 12-2907 5-340 
Table 4 
tobramycin (MT) and/or ciprofloxacin (MTC)/(MC) for P aewginosa infection 
Inflammatory parameters before and after treatment with meropenem as monotherapy (M) or in association with 
Leukocyte count ESR C-reactive protein 
(1 0’/L) (mm/h) (mg/L) 
Treatment Before After Before After Before After 
M Median 8.4 7.3 28 21 138 48 
47 (range) (5-17) (4-12) (2-90) (5-68) (24-1271) (1 9-327) 
M T  Median 8.1 7.9 22 18 98 48 
31 (range) (5-27) (5-14) (5-66) (3-54) (12-2907) (5-340) 
M C  Median 7.1 6.7 9.5 12 64.5 48 
11 (range) (4-10) (4-12) (4-26) (6-18) (48-226) (24-70) 
MTC Median 9.2 7.4 40 24 181 68 
21 (range) (6-17) (4-17) (5-89) (3-51) (14-1120) (18-343) 
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Table 5 Pulmonary function parameters before and after treatment with meropenem for B. cepacia infection (nine courses) 
FEVi FVC 
Before After Before Aftcr 
Mean 37 45 63 72 
SD 10.8 13.4 17.8 24.2 
FEVI and FVC are expressed as percentages of the predictive values for height and sex. 
Table 6 Inflammatory parameters before and after treatment with meropenem for B. ceparia infection (nine courses) 
~ ~ ~~ ~ ~ ~~ ~ ~ 
Leukocyte count ESK C-reactive protein 
(1  0’/L) (mm/h) (mg/L) 
Before After Before After Before Aftcr 
Median 12 7.6 51 21 399 196 
Kange (6-1 6) (6-1 1) (1 8-72) (2-75) (172-1735) (48-284) 
Safety 
One hundred and six of the 114 courses administered 
for P aeruginosa infection were tolerated without any 
clinically observed adverse reactions. In three cases, all 
during monotherapy with meropenem, side effects 
(drug fever, nausea and dizziness in a patient with 
allergy to imipenem and a rash on the buttocks, 
respectively) led to cessation of treatment. Another five 
courses were associated with itching and rash but these 
symptoms did not necessitate interruption of treatment. 
No other hypersensitivity reactions occurred, despite 
the fact that all 57 patients with chronic infection with 
P aevuginosa had a history of hypersensitivity reactions 
to one or more p-lactam antibiotics. Additionally, one 
patient experienced changes in taste perception during 
two consecutive courses. Single episodes of diarrhea, 
headache and nausea were experienced by three 
different patients, but the relation to the meropenem 
treatment was unclear. In 25 of the 114 courses a mild 
and transient increase in transaminases was seen during 
the treatment period. No increase in other liver 
enzyme parameters or other side effects was seen. 
Nine of the 10 meropenem courses administered 
for B. cepacia infection were well tolerated without 
any clinical complaints. In one course, drug fever 
developed and the treatment was interrupted. A mild 
increase in liver transaminases was also observed in two 
of the courses. 
Bacteriology 
The MICs (IC50) (pg/mL) of P aeruginosa and B. cepacia 
strains isolated in 1994 from 90 and five CF patients, 
Table 7 
1994 from 90 and five patients, respectively 
MIC and ICso (pg/mL) values of different antibiotics against 90 I? aeruginosa and five B. c-cparia strains collected in 
I? aeruginosa B. cepacia 
MIC (pg/mL) Ic50 (pg/mL) MIC (pg/mL) Ic50  (pg/mL) 
mean mean mean mean 
(range) (range) (range) (range) 
Tobramycin 6 2.2 59 13 
(0.4-50) (0.3-18) (1 2.5-400) (5.3-50) 
Ciprofloxacin 1.2 0.4 9.6 1.5 
Piperacillin 49 12 16.3 3.4 
Ceftazidime 26 5.6 23 1.7 
Aztreonam 26 5.8 35.4 6 
(0.005-25) (0.005-3.7) (0.8-50) (0.3-10.5) 
(0.2-400) (0.1-336) (0.8-400) (0.6-30) 
(0.4-400) (0.2-336) (0.8-400) (0.3-21) 
(0.2400) (0.OS-400) (1.6400) (1.1-42) 
Impenem 6.4 2.3 ND NU 
Meropenem 5.1 1.5 4.8 1.2 
(0.450) (0.3-18) 
(0.1-50) (0.05-25) (1.6-12.5) (0.4-2.2) 
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respectively, are presented in Table 7. These results 
showed meropenem and imipenem to be the most 
effective p-lactam compounds. The MICs of most 
other antibiotics were three to five-fold higher than 
the ICso, indicating heterogeneity in the susceptibility 
of the inoculum. 
The MIC values of rneropenern followed in 10 
patients before and after the 2 weeks of intravenous 
treatment are shown in Figure 1. At the beginning 
of the treatment five of the 10 l? aeruginosa strains 
were already resistant to meropenem, two had inter- 
mediate-resistance and three were sensitive. At the end 
of the 2-week course the MICs remained unchanged 
for the resistant strains, while one sensitive and one 
intermediate-resistance strain became resistant. At the 
beginning of the treatment a mucoid I? aeruginosa strain 
was isolated in eight cases, and a non-mucoid one in 
22 cases, and in 81 cases a mucoid and a non-mucoid 
strain were present simultaneously. Judged by the 
tablet diffusion sensitivity test, the mucoid strains of 
I? aeruginosa maintained full sensitivity after 42 courses. 
The bacterium was temporarily eradicated in 35 
courses and developed decreased sensitivity in three 
courses. The non-mucoid strains remained fully 
sensitive in 67 cases but developed decreased sensitivity 
in 27 cases (totally resistant in four cases), and none was 
eradicated during any of the courses. In nine cases the 
data on the bacterial susceptibility at the end of the 
treatment were incomplete. B. cepacia maintained full 
sensitivity after all of the courses. None of the strains 
was eradicated. 
' "1 J E 0 
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DISCUSSION 
In this retrospective analysis of the use of meropenem 
on a compassionate basis in CF patients with chronic 
bronchopulmonary infection due to P aeruginosa or 
B. cepacia, we found the drug to be effective and well 
tolerated. Lung function improved significantly and 
inflammatory parameters decreased significantly 
following treatment. The increase in the FVC and 
FEVl obtained with ineropenem in this study was 
similar to that published by Regelmann [14] who 
evaluated in a double-blind placebo-controlled trial the 
contribution of antibiotic treatment to the clinical 
improvement of CF patients. 
The clinical effect was of the same magnitude as 
that previously observed in our center with other novel 
p-lactams at the time of introduction in our routine 
treatment [15,16] before development of resistance 
became a major problem [17]. This is encouraging, 
since comparative trials are impossible to carry out in 
this group of CF patients. The high incidences of 
multiresistant strains and of allergy to 0-lactam anti- 
biotics limit the possibilities of choice of an appropriate 
treatment to a single 0-lactam antibiotic. 
Side effects led to the cessation of the treatment 
in only four cases, although all 57 CF patients with 
l? aeruginosa chronic lung infection had hypersensitivity 
reactions to p-lactam antibiotics. N o  other serious 
adverse reactions occurred. An increase in transaminases 
was seen during treatment in some patients. However, 
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Figure 1 
before and after a 2-week intravenous treatment with meropenem. The box and whisker plots represent the median, 25, 75 
and 90 centiles of the values. 
Minimal inhibitory concentrations (MICs) of meropenem against P aertrginora isolated from 10 CF patients 
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been seen with other p-lactanis 1181. In comparison 
to the other carbapenem compound available, imi- 
peneidcilastatin, nieropenem seeined to be much 
better tolerated by the patients, as neurologic side effects 
in terms of headache, nausea, vomiting and fatigue, 
which were experienced in seven out of 10 patients 
during treatment with imipenendcilastatin [ 161, were 
uncommon during treatment with nieropenem. 
The MICs of meropenem for I? aeruginosa strains 
collected before and after the treatment with inero- 
peneni from 10 CF  patients did not change sig- 
nificantly, but a tendency for there to be higher values 
of the post-treatment MICs was observed. 
Meropenem also appeared to maintain its efficacy 
during the second and third intravenous courses in 
terms of lung function improvement, A retrospective 
review of the efficacy of different therapeutic combina- 
tions indicated that the improvement in the lung 
function appeared to be equally good with nieropeneni 
as with nionotherapy or in association with the other 
drugs. This finding is in agreement with studies in vitro 
showing that the conibination of nieropeneni with 
tobramycin has an additive effect [19]. Lack of cross- 
resistance between meropeneni and other classes of p- 
lactaiiis has also been reported [20]. This could explain 
the good efficacy of meropeneni in our study, but in 
view of our experience with other novel drugs and the 
few data present in this study on the MICs of 
nieropeneiii before and after treatment, the develop- 
ment of resistance of P aeruxinosa to meropenem may 
be a problem for the future 12,161. 
B. cepucia is generally resistant to most antibiotics, 
and even when activity is observed in vitro, the clinical 
response is poor [21]. As the carbapeneiiis are the most 
active of all p-lactanis, nieropenem offers hope for 
the future. No results of carbapenem treatiiient of 
B. cepacia infection have been previously reported. In 
our study nieropeneni was shown to be effective for the 
treatment of pulmonary infections in C F  patients. No 
dcvelopnient of resistance of B. cepacia to nieropeneni 
occurred during treatment and no clinically important 
adverse events were observed, indicating meropenem 
to be a promising drug in the treatment of B. cepacin 
infection in CF patients. An investigation of B. cepacia 
isolates of a tnultiresistant epidemic strain recovered 
from CF patients showed that the activities of 
iniipeneni, cefiazidime and piperacillin in vitro were 
enhanced in the presence of the novel p-lactaniase 
inhibitor B R L  42715 1221. The conibiiiation of 
tneropenem with a suitable p-lactaniase inhibitor 
would probably be clinically advantageous in infections 
with resistant B. cepacia. 
In conclusion, we believe that nieropenem should 
be considered as an alternative therapy for P aeruginosa 
and B. repacia infection in CF  patient5 with hyper- 
sensitivity reactions towards other p-lactams or harbor- 
ing strains resistant to existing p-lactam antibiotics. 
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